Silicon Valley Bank collapse sends shivers down biotech spines

    Nature Biotechnology

    volume 41page 437 (2023)Cite this article

    On 10 March, Silicon Valley Bank (SVB), a popular bank with venture capital (VC)-backed technology and biotech firms, collapsed. Shockwaves spread across biotech companies, the banking sector and beyond. SVB was already in trouble: the tough fundraising environment for biotech and tech firms meant SVB’s deposits had fallen, while rising interest rates were wreaking havoc with its investments. When those challenges became public, SVB’s shares fell and anxious depositors, including VC firms, began pulling their cash. What resulted was one of the fastest, and largest, bank runs in history. It spread to other regional banks — Signature Bank failed, and San Francisco-based First Republic Bank is still on the rocks — and then to a much bigger one, Credit Suisse.

    This is a preview of subscription content, access via your institution

    Access options

    Subscribe to this journal

    Receive 12 print issues and online access

    214,86 € per year

    only 17,91 € per issue

    Rent or buy this article

    Get just this article for as long as you need it


    Prices may be subject to local taxes which are calculated during checkout

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Silicon Valley Bank collapse sends shivers down biotech spines.
    Nat Biotechnol 41, 437 (2023).

    Download citation

    • Published:

    • Issue Date:

    • DOI:

    Read More